Premium
Vincristine sulfate for the treatment of thrombotic thrombocytopenic purpura refractory to plasma‐exchange
Author(s) -
BobbioPallavicini E.,
Porta C.,
Centurioni R.,
Gugliotta L.,
Vianelli N.,
Tacconi F.,
Billio A.,
Ascari E.
Publication year - 1994
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1111/j.1600-0609.1994.tb00649.x
Subject(s) - medicine , vincristine , thrombotic thrombocytopenic purpura , refractory (planetary science) , surgery , gastroenterology , chemotherapy , platelet , cyclophosphamide , physics , astrobiology
Among all the patients treated by the Italian Cooperative Group for TTP, we retrospectively reviewed the results obtained using vincristine (VCR) in 8 TTP patients (4 men and 4 women, average age: 39.25 years, range: 23–48) who did not respond to combined apheretic and pharmacologic treatment. All patients, after failing to respond to treatment, were started on VCR at the dose of 2 mg, i.v., once a week. Despite this treatment, 4 patients (50%) died 1, 7, 12 and 25 days after the first VCR dose, respectively. The other 4 patients who received VCR achieved complete remission 24, 30, 40 and 50 days from the beginning of the treatment. Total doses of VCR ranged from 2 to 6 mg in the deceased group, and from 6 to 14 mg in the cured patients. In our experience, VCR is a promising agent to treat TTP patients resistant to conventional plasma‐exchange and pharmacologic therapy.